Bountra C, Gale J D, Gardner C J, Jordan C C, Kilpatrick G J, Twissell D J, Ward P
Division of Biology, Glaxo Research and Development Ltd., Ware, Herts., UK.
Oncology. 1996 Jun;53 Suppl 1:102-9. doi: 10.1159/000227649.
The introduction of 5-HT3 antagonists, such as ondansetron, as antiemetic agents has transformed the management of patients receiving chemotherapy or radiation therapy. Studies in animal models with NK1 antagonists suggest that these represent a new class of antiemetic agents having a broader spectrum of activity than 5-HT3 antagonists. Compounds of this class may prove to be more effective in man against delayed emesis induced by cisplatin, post-operative nausea and vomiting and motion sickness. Thus, they have the potential to complement 5-HT3 antagonists and so provide a further advance in the management of nausea and vomiting.
5-羟色胺3拮抗剂（如昂丹司琼）作为止吐药的引入，改变了接受化疗或放疗患者的治疗管理。在动物模型中使用NK1拮抗剂的研究表明，这些药物代表了一类新的止吐药，其活性谱比5-羟色胺3拮抗剂更广。这类化合物在人体中可能对顺铂引起的延迟性呕吐、术后恶心和呕吐以及晕动病更有效。因此，它们有可能补充5-羟色胺3拮抗剂，从而在恶心和呕吐的治疗管理方面取得进一步进展。
